Selective Extended Dissection in Different Types of Pancreatic Head Cancer: A Retrospective Cohort Study.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

520 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-01-01

Study Completion Date

2022-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant tumor with relatively poor survival. Surgery is the first choice for the treatment of patients with early pancreatic cancer. However, the surgical approach and the extent of resection for patients with pancreatic cancer are controversial at present.

The investigators optimized the procedure of standard pancreaticoduodenectomy to selective extended dissection (SED), which is based on the extra-pancreatic nerve plexus (PLX) potentially invaded by tumor. The investigators retrospectively analyzed the clinicopathological data of patients with pancreatic adenocarcinoma who underwent radical surgery in our center from 2011 to 2020. Patients who underwent standard dissection (SD) were matched 2:1 to those who underwent SED using propensity score matching (PSM). The log-rank test and cox regression model were used to analyze survival data. In addition, statistical analyses were performed for the perioperative complications, postoperative pathology and recurrence pattern.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Integrative Proteomic Characterization of Pancreatic Ductal Adenocarcinoma

NCT04525209

Tumor Tissues and Non-tumor Tissues From PDAC Patients Were Used for Genomic and Transcriptome Sequencing Analysis and Proteomics and Phosphorylated Proteomics

UNKNOWN

Pancreas-sparing Duodenectomy Versus Pancreatoduodenectomy for Early-stage Periampullary Carcinoma

NCT01291927

Periampullary Carcinoma Nos

UNKNOWN NA

Conventional Partial Pancreatoduodenectomy Versus an Extended Pancreatoduodenectomy for Pancreatic Head Cancers

NCT06703905

Pancreatic Cancer Resectable

NOT_YET_RECRUITING NA

Influence Factors of PD-1 Therapeutic Efficacy in Advanced Pancreatic Cancer

NCT05201729

Pancreatic Ductal Adenocarcinoma, PDAC

UNKNOWN

Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis

NCT02869802

Cancer Pancreatic Cancer

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Carcinoma, Pancreatic Ductal

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Selective extended dissection (SED) group

Selective extended dissection of pancreaticoduodenectomy

Intervention Type PROCEDURE

An optimized procedure of pancreaticoduodenectomy which is based on the extra-pancreatic nerve plexus (PLX) potentially invaded by tumor.

Standard dissection (SD) group

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Selective extended dissection of pancreaticoduodenectomy

An optimized procedure of pancreaticoduodenectomy which is based on the extra-pancreatic nerve plexus (PLX) potentially invaded by tumor.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\- 1) Patients diagnosed as resectable pancreatic cancer were pathologically diagnosed as PDAC after surgery.

2\) Patients received radical surgery (R0) and had complete photos or videos of the operation.

Exclusion Criteria

\- 1) The operation records as well as related photo or video data could not reflect the surgical approach and the extent of resection.

2\) Patients with incomplete clinical, pathological, imaging and follow-up information.

Eligible Sex

ALL

Accepts Healthy Volunteers

No